8 months ago
Quadria Capital Focuses on Healthcare and Med-Tech
Quadria Capital, a company that invests in healthcare, recently talked about their plans after one of their investments, Nephroplus, became publicly listed.
They made a lot of money from this investment and plan to keep investing in healthcare for a long time.
They have a big new fund of $1.07 billion and want to use it to support different areas like making healthcare products in India and Vietnam, digital healthcare, and special healthcare services.
They also think that making medical technology (Med-Tech) in India is a big opportunity.
They prefer to sell their investments to other companies rather than through public listings.
They believe that healthcare investments take time and are ready to wait for the right opportunities.
Quadria Capital made significant returns from Nephroplus' listing, remaining the largest shareholder.
The firm closed its third fund at $1.07 billion, focusing on localisation, outsourcing, and digital healthcare.
Key investment areas include single speciality healthcare, speciality pharma, and contract manufacturing.
Quadria prefers strategic sales for exits, with 50-60% of exits being to strategic buyers.
Med-Tech and preventive healthcare are identified as key emerging opportunities.
- Who
- Quadria Capital, Amit Varma, Sunil Thakur
- What
- Investment strategy and future bets in healthcare and Med-Tech
- Where
- India and Vietnam
- When
- After the successful listing of Nephroplus
- Why
- To strengthen domestic supply chains, focus on high-growth areas, and capitalize on emerging opportunities
Key facts
- Company
- Quadria Capital
- Fund Size
- $1.07 billion
- Key Themes
- Localisation, Outsourcing, Consumer Healthcare, Digital Healthcare, Roll-up Strategy
- Investment Period
- 5-7 years
- Exit Preference
- Strategic Sales (50-60%) over IPOs (10%)
- Emerging Focus
- Med-Tech and Preventive Healthcare
- Geographical Focus
- India and Vietnam
Quotes
Amit Varma
Co-founder & Managing Partner at Quadria Capital
“We do believe that Med-Tech is actually going to be the next area for focus because there's a lot of local indigenisation needed in the Med-Tech space. And there are not enough companies of scale and size which can deliver the same way that we did pharma 10 years ago.”
CNBC TV 18
“It hasn't played out as fast as it should. We are not distressed because it hasn't played out because we do believe fundamentally investment in healthcare takes a long time and has huge regulatory challenges.”
CNBC TV 18
Sunil Thakur
Partner & Investment Committee Member at Quadria Capital
“Single speciality continues to be an area of interest for us, which is what we've been doing successfully for the last 10 years.”
CNBC TV 18
